SBRT for Liver Tumors, Liver Metastases, and Pancreatic Tumors

NCT07407257 | Completed

• 2 other identifiers: OI_SBRT-LIVER-PANCREAS-2019ERID-KSOPKR-0091/2019
• Study Type: interventional
• Target: 65
• Locations: 1 country
• Sites: 1

Brief Summary

This prospective observational study evaluates the safety and effectiveness of stereotactic body radiotherapy (SBRT) for liver tumors, liver metastases, and pancreatic tumors. The study focuses on systematic monitoring and optimization of the SBRT treatment process, including adherence to the implemented protocol, with the aim of simplifying methods while maintaining treatment safety.

Conditions

Liver Neoplasms; Liver Metastases; Pancreatic Neoplasms

Keywords

SBRT; stereotactic body radiotherapy; liver tumor; pancreatic tumor

Outcome Measures

Primary Outcomes (1)

• Treatment Safety (Radiotherapy-Related Toxicity)

  Assessment of acute and late treatment-related toxicity after stereotactic body radiotherapy (SBRT) for liver tumors, liver metastases, and pancreatic tumors, evaluated according to standard toxicity criteria.

  From start of SBRT up to 12 months after treatment

Study Arms (1)

SBRT Treatment

EXPERIMENTAL

Patients with liver tumors, liver metastases, or pancreatic tumors treated with stereotactic body radiotherapy (SBRT) according to the institutional protocol.

Radiation: Stereotactic Body Radiotherapy (SBRT)

Interventions

Stereotactic Body Radiotherapy (SBRT) RADIATION

Stereotactic body radiotherapy (SBRT) delivered according to the institutional protocol for treatment of liver tumors, liver metastases, and pancreatic tumors, with high-dose hypofractionated radiation and image-guided radiotherapy techniques.

SBRT Treatment

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years
• Patients with liver tumors, liver metastases, or pancreatic tumors eligible for stereotactic body radiotherapy (SBRT)
• Planned treatment with SBRT according to institutional protocol
• Ability to comply with treatment and follow-up procedures
• Signed informed consent

You may not qualify if:

• Contraindications for SBRT according to institutional radiotherapy protocol
• Prior radiotherapy that prevents safe SBRT delivery to the target region
• Severe uncontrolled comorbidities preventing safe SBRT treatment
• Pregnancy
• Inability to provide informed consent or comply with study procedures

Sponsors & Collaborators

• Institute of Oncology Ljubljana: lead

Study Sites (1)

Institute of Oncology Ljubljana

Ljubljana, 1000, Slovenia

Location

MeSH Terms

Conditions

Liver Neoplasms; Pancreatic Neoplasms; Carcinoma, Hepatocellular

Interventions

Radiosurgery

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Liver Diseases; Endocrine Gland Neoplasms; Pancreatic Diseases; Endocrine System Diseases; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type

Intervention Hierarchy (Ancestors)

Radiotherapy; Therapeutics; Stereotaxic Techniques; Neurosurgical Procedures; Surgical Procedures, Operative; Investigative Techniques

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 6, 2026
• First Posted: February 12, 2026
• Study Start: January 1, 2019
• Primary Completion: December 31, 2024
• Study Completion: December 31, 2025
• Last Updated: February 18, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

SL (1)